## EFX: Equifax, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 0.9% below STRENGTH zone (3.0-6.0%); PEG 1.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($208.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Sendero Wealth Management LLC Purchases 14,603 Shares of Equifax, Inc. $EFX**
- Source: MarketBeat | 20251218T121811 | Somewhat-Bullish | Relevance: 100%
- Sendero Wealth Management LLC significantly increased its stake in Equifax, Inc. (NYSE:EFX) by 148.1% during the third quarter, acquiring 14,603 shares and now holding a total of 24,460 shares valued at $6.275 million. This makes Equifax its 27th largest holding, representing about 0.7% of its assets. The company recently reported strong Q3 earnings, beating analyst expectations, and has set positive guidance for Q4 2025 and full-year 2025, despite some analysts lowering price targets and notable insider sales totaling over $12 million.

**2. (EFX) Volatility Zones as Tactical Triggers**
- Source: Stock Traders Daily | 20251218T012600 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Equifax Inc. (NYSE: EFX) using AI models, identifying a positive near-term sentiment with a potential shift to broader weak alignment due to a mid-channel oscillation pattern. It highlights an exceptional short setup with a 36.0:1 risk-reward ratio and provides distinct institutional trading strategies for different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels across near, mid, and long-term horizons.

**3. Equifax Secures 27 New Patents in the Second Half of 2025**
- Source: PR Newswire | 20251218T210751 | Bullish | Relevance: 100%
- Equifax (NYSE: EFX) secured 27 new patents in the second half of 2025, bringing their total for the year to 62. Twenty of these patents focus on artificial intelligence, bolstering their EFX.AI strategy and enabling the development of cloud-based, AI-enabled solutions for consumers. The company now holds nearly 700 issued or pending patents across 15 countries, with over 320 supporting responsible AI initiatives.

**4. Equifax secures 27 new patents in second half of 2025**
- Source: Investing.com India | 20251217T220833 | Somewhat-Bullish | Relevance: 100%
- Equifax Inc. (NYSE:EFX) has secured 27 new patents in the second half of 2025, bringing its total for the year to 62, with 20 of these supporting its artificial intelligence initiatives. The company currently holds nearly 700 issued or pending patents globally, with over 320 focused on responsible AI. Despite a 19.5% stock decline over the past year, Equifax maintains impressive gross profit margins of 57.1% and is considered slightly undervalued by InvestingPro analysis.

**5. Equifax Secures 27 New Patents in the Second Half of 2025**
- Source: Yahoo Finance | 20251217T212000 | Bullish | Relevance: 100%
- Equifax secured 27 new patents in the second half of 2025, contributing to a total of 62 patents for the year. A significant 20 of these patents are related to artificial intelligence (AI), bolstering Equifax's EFX.AI strategy and accelerating the development of cloud-based, AI-enabled solutions. These innovations aim to create new financial opportunities for consumers and enhance decision-making through advanced data and analytics.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $280 | $290 | -3% |
| 2025-12-08 | BMO Capital | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Overweight |
| 2025-12-08 | BMO Capital | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.90M) |
| Sells | 5 ($1.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.1%)
- Capital Internationa: 8.5% (-0.4%)
- Blackrock Inc.: 7.5% (+1.4%)
- Price (T.Rowe) Assoc: 4.9% (+1.0%)
- Harris Associates L.: 4.8% (+14.2%)

### Key Risks

1. Long-term trend broken: trading 9.5% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.0B |
| Beta | 1.59 |
| 52W Range | $199.98 - $281.07 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 24.8 |
| Current P/E | 28.8 |
| YoY Growth | 16.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.4% to 0.9% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.28), confirming momentum. RSI neutral at 57. OFD pattern: -SLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.89% (CS: 69) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 0.905x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $219.12
- **Stop Loss:** $208.74 (4.7% risk)
- **Target:** $229.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $18,844.32
- **Portfolio %:** 18.84%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $2.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.94 | $2.04 | +5.3% |
| 2025Q2 | $1.92 | $2.00 | +4.1% |
| 2025Q1 | $1.40 | $1.53 | +9.0% |
| 2024Q4 | $2.10 | $2.12 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*